Table 3.

Observed (Obs) and expected (Exp) numbers and O/E ratios of UGIB in periods of use of NSAID only according to sex, age, number of prior prescriptions, type of NSAID, and route of administration. Exposure window is 90 days.

Periods of only use of NSAID	Number of persons	Person-years	Obs	UGIB Exp	O/E	95% CI
Sex
Men	68 551	37 447	135	46.5	2.90	2.4, 3.4
Women	84 331	57 540	230	54.7	4.21	3.7, 4.8
Age (years)
< 60	108 837	57 840	67	17.4	3.85	3.0, 4.9
60–69	18 573	14 253	40	13.6	2.93	2.1, 4.0
> 69	25 472	22 894	258	70.2	3.68	3.2, 4.2
Number of prior NSAID prescriptions
0	149 120	29 005	54	19.8	2.73	2.0, 3.6
1	82 424	14 880	50	12.8	3.99	3.0, 5.3
2	54 237	9252	43	9.1	4.72	3.4, 6.4
3	39 510	6444	25	7.1	3.50	2.3, 5.2
4	30 874	4899	21	5.9	3.57	2.2, 5.5
5 +	26 898	30 509	172	46.8	3.68	3.1, 4.3
Type of NSAID
Diclofenac	27 154	9854	43	8.8	4.87	3.5, 6.6
Ibuprofen	89 415	44 086	112	46.4	2.41	2.0, 2.9
Indomethacin	7420	5005	33	7.7	4.28	2.9, 6.0
Ketoprofen	18 634	6436	42	6.7	6.30	4.5, 8.5
Naproxen	30 033	12 812	35	11.5	3.03	2.1, 4.2
Piroxicam	10 399	4590	28	5.6	5.00	3.3, 7.2
Form and route of administration
Tablets	131 139	73 313	253	77.8	3.25	2.9, 3.7
Slow-release tablets1	29 035	11 727	56	13.2	4.23	3.2, 5.5
Enteric-coated tablets2	14 297	5413	20	5.6	3.58	2.2, 5.5
Suppositories3	4659	1639	12	1.4	8.47	4.4, 14.8
Others (soluble tablets, mixture, etc.)	621	167	3	0.2	13.49	2.7, 39.4

¹Indomethacin, diclofenac, ketoprofen, ibuprofen, tiaprofenic acid, flurbiprofen and tolfenamic acid.

²Diclofenac and naproxen.

³Indomethacin, diclofenac, ketoprofen, naproxen, piroxicam and tenoxicam.